dc.contributor.author | Donners, R | |
dc.contributor.author | Tunariu, N | |
dc.contributor.author | Tovey, H | |
dc.contributor.author | Hall, E | |
dc.contributor.author | Chua, S | |
dc.contributor.author | Cook, G | |
dc.contributor.author | Du, Y | |
dc.contributor.author | Blackledge, MD | |
dc.contributor.author | Parker, CC | |
dc.contributor.author | Koh, D-M | |
dc.coverage.spatial | Germany | |
dc.date.accessioned | 2023-11-15T10:17:08Z | |
dc.date.available | 2023-11-15T10:17:08Z | |
dc.date.issued | 2023-08-24 | |
dc.identifier | 10.1007/s00330-023-10172-7 | |
dc.identifier.citation | European Radiology, 2023, | |
dc.identifier.issn | 0938-7994 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/6057 | |
dc.identifier.eissn | 1432-1084 | |
dc.identifier.eissn | 1432-1084 | |
dc.identifier.doi | 10.1007/s00330-023-10172-7 | |
dc.identifier.doi | 10.1007/s00330-023-10172-7 | |
dc.description.abstract | OBJECTIVES: To investigate whether baseline 18F-sodium fluoride (NaF) and 18F-choline PET activity is associated with metastatic castration-resistant prostate cancer (mCRPC) global and individual bone metastases' DWI MR imaging response to radium-223 treatment. METHODS: Thirty-six bone-only mCRPC patients were prospectively recruited from three centers. Whole-body (WB)-MRI with DWI and 18F-NaF and 18F-choline PET/CT were performed at therapy baseline and 8-week intervals. In each patient, bone disease median global (g)ADC change between baseline and follow-up was calculated. Additionally, up to five bone target lesions per patient were delineated and individual median ADC change recorded. An ADC increase > 30% defined response per-patient and per-lesion. For the same targets, baseline 18F-NaF and 18F-choline PET SUVmax were recorded. Mean SUVmax across patient targets was correlated with gADC change and lesion SUVmax with per-lesion ADC change. RESULTS: A total of 133 lesions in 36 patients (14 responders) were analyzed. 18F-NaF PET per-patient mean SUVmax was significantly higher in responders (median = 56.0 versus 38.7 in non-responders; p = 0.008), with positive correlation between SUVmax and gADC increase (rho = 0.42; p = 0.015). A 48.7 SUVmax threshold identified responders with 77% sensitivity and 75% specificity. Baseline 18F-NaF PET per-lesion SUVmax was higher in responding metastases (median = 51.6 versus 31.8 in non-responding metastases; p = 0.001), with positive correlation between baseline lesion SUVmax and ADC increase (rho = 0.39; p < 0.001). A 36.8 SUVmax threshold yielded 72% sensitivity and 63% specificity. No significant association was found between baseline 18F-choline PET SUVmax and ADC response on a per-patient (p = 0.164) or per-lesion basis (p = 0.921). CONCLUSION: 18F-NaF PET baseline SUVmax of target mCRPC bone disease showed significant association with response to radium-223 defined by ADC change. CLINICAL RELEVANCE STATEMENT: 18F-sodium fluoride PET/CT baseline maximum SUV of castration-resistant prostate cancer bone metastases could be used as a predictive biomarker for response to radium-223 therapy. KEY POINTS: • 18F-sodium fluoride PET baseline SUVmax of castration-resistant prostate cancer bone metastases showed significant association with response to radium-223. • Baseline 18F-sodium fluoride PET can improve patient selection for radium-223 therapy. • Change in whole-body DWI parameters can be used for response correlation with baseline 18F-sodium fluoride PET SUVmax in castration-resistant prostate cancer bone metastases. | |
dc.format | Print-Electronic | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | SPRINGER | |
dc.relation.ispartof | European Radiology | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject | Bone | |
dc.subject | Diffusion magnetic resonance imaging | |
dc.subject | Metastases | |
dc.subject | Positron emission tomography computed tomography | |
dc.subject | Radium | |
dc.title | The value of baseline 18F-sodium fluoride and 18F-choline PET activity for identifying responders to radium-223 treatment in castration-resistant prostate cancer bone metastases. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2023-07-15 | |
dc.date.updated | 2023-11-14T11:27:58Z | |
rioxxterms.version | VoR | |
rioxxterms.versionofrecord | 10.1007/s00330-023-10172-7 | |
rioxxterms.licenseref.startdate | 2023-08-24 | |
rioxxterms.type | Journal Article/Review | |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/37615760 | |
pubs.organisational-group | ICR | |
pubs.organisational-group | ICR/Primary Group | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit | |
pubs.organisational-group | ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published online | |
pubs.publisher-url | http://dx.doi.org/10.1007/s00330-023-10172-7 | |
icr.researchteam | Clin Trials & Stats Unit | |
icr.researchteam | RMH Honorary Faculty | |
dc.contributor.icrauthor | Tovey, Holly | |
dc.contributor.icrauthor | Hall, Emma | |
dc.contributor.icrauthor | Blackledge, Matthew | |
icr.provenance | Deposited by Mrs Jessica Perry (impersonating Prof Emma Hall) on 2023-11-14. Deposit type is initial. No. of files: 1. Files: The value of baseline 18F‑sodium fluoride and 18F‑choline PET.pdf | |